TRU-SENTIMENT · DeltaNeutral
ELV Trading Analysis - 10/02/2026 01:05 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
ELV (Elevance Health Inc.) at $386.64. True Sentiment Balanced, delta 40-60 call 45% / put 55%, call $2,530 vs put $3,100. RSI 14.0.
- Symbol
- ELV
- Price
- $386.64
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- medium
- Published
- 2026-10-02 13:05:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis — Delta 40–60 Options:
Call volume: $2,530.00 (44.90%)
Put volume: $3,100.00 (55.10%)
Total: $5,630.00
Put dollar volume exceeds call dollar volume by $570.00, or 10.20 percentage points of total directional volume. That difference is modest rather than decisive. The platform classified the result as balanced.
Only 2 transactions qualified for the pure directional Delta 40–60 methodology, despite 824 total options being analyzed. The filter ratio was 0.20%. This very small qualified sample materially limits the reliability of any bullish or bearish inference from options activity.
The options flow does not confirm the oversold bullish case: calls did not dominate puts. Conversely, the bearish advantage is too small to constitute strong conviction. The appropriate interpretation is that near-term expectations are divided rather than directionally decisive.
Key Statistics: ELV
Fundamental Snapshot
Valuation
| P/E (trailing) | 16.70 |
| EPS (trailing 12 mo) | $22.89 |
| Market cap | $83.91B |
| Shares outstanding | 216.9M |
Dividend
| Dividend yield | 1.80% |
| Annual dividend | $6.88 |
| Ex-dividend date | 2026-09-10 |
Risk & range
| Beta | 0.77 |
| 52-week low | $274.84 |
| 52-week high | $436.24 |
| Historical volatility | 23.4% |
Ownership & trading
| Institutional ownership | 63.8% |
| Average daily volume | 1.3M sh |
Reported figures; no analyst estimates.
📈 Analysis
ELV Technical, Fundamental, and Options Analysis
News Headlines & Context:
News context is separated from the embedded-data analysis. Because the supplied market data is dated October 2026, no specific 2026 news reports are included below. These are general Elevance Health themes rather than verified or time-stamped headlines.
- Quarterly earnings and guidance: Elevance Health’s quarterly results can materially affect the shares through changes to earnings expectations, medical-cost trends, membership outlooks, and full-year guidance.
- Medical-cost pressure: Updated medical-loss-ratio commentary remains an important catalyst, particularly for Medicare Advantage and commercial health-plan businesses.
- Medicare Advantage policy and reimbursement: Rate notices, risk-adjustment changes, and updates to Medicare Advantage utilization can influence the company’s earnings outlook.
- Medicaid pricing and managed-care regulation: State contract rates, redeterminations, and healthcare regulatory developments could affect membership and profitability expectations.
- Healthcare reform: Proposals involving pharmacy benefit managers, health-plan pricing, or broader healthcare regulation may create short-term volatility.
These potential catalysts could help explain a rebound from oversold technical conditions if they improve earnings expectations. However, the embedded options flow is balanced and does not demonstrate strong bullish positioning. Until a verified fundamental catalyst accompanies the technical bounce, the news backdrop should remain conditional rather than being treated as confirmation of a new uptrend.
Fundamental Analysis:
| Metric | Embedded value | Interpretation |
|---|---|---|
| Market capitalization | $83.91 billion | Large-cap managed-care company. |
| Trailing EPS | $22.89 | Positive trailing earnings, but no quarterly EPS series was supplied to assess the latest trend. |
| Trailing P/E | 16.70 | A moderate headline valuation; a direct peer comparison cannot be made from the embedded data. |
| Forward P/E | Not provided | Forward valuation and growth expectations cannot be evaluated. |
| PEG ratio | Not provided | No conclusion about valuation relative to projected growth is supportable. |
| Dividend yield | 1.80% | Modest income component, with an indicated dividend rate of $6.88 per share. |
| Beta | 0.77 | Historically below-market sensitivity is indicated, although the supplied historical volatility remains substantial. |
| Institutional ownership | 63.81% | A high institutional ownership share. |
| Historical volatility | 23.43% | Meaningful volatility increases the importance of risk-defined structures and position-level stop discipline. |
Earnings, Margins, and Growth
The supplied fundamentals include trailing EPS of $22.89 but do not provide year-over-year EPS history, recent quarterly earnings, revenue, revenue growth, or gross, operating, and net profit margins. Those fields therefore cannot be calculated reliably from the embedded data.
At the daily indicator price of $381.73, the supplied trailing P/E of 16.70 is consistent with the reported EPS. The valuation may appear moderate in isolation, but no peer P/E figures or PEG ratio were provided. Consequently, a defensible conclusion that ELV is cheap or expensive relative to competitors cannot be made.
Balance Sheet and Capital Returns
Debt-to-equity, return on equity, and free cash flow are not supplied. Those omissions are important for a healthcare insurer and prevent a complete assessment of leverage, capital adequacy, cash conversion, and earnings quality.
Analyst Consensus
No analyst recommendation, mean price target, or number of analyst opinions is available in the embedded data. An analyst-consensus bullish or bearish comparison is therefore not possible.
Current Market Position:
ELV closed at $381.73 on October 1, 2026, down from $390.74 on September 30. That session traded as low as $375.74 and as high as $390.37, confirming substantial downside volatility. The following intraday data show a recovery to $386.64 by 12:35 PM.
The first five five-minute bars declined from an opening price of $388.00 to $384.20. During the final five bars, however, ELV moved from $386.07 to $386.64, with a recent closing high of $386.68. This indicates stabilization and a modest intraday bounce, but not yet a confirmed trend reversal.
Technical Analysis:
Technical Indicators
Interactive charts load with JavaScript. This text is the crawlable summary.